Core Viewpoint - The Chinese traditional medicine industry is experiencing significant growth driven by policy support and increasing health demands, with a focus on balancing heritage and innovation [1] Group 1: Company Strategy - Jilin Aodong Pharmaceutical Group Co., Ltd. adopts a dual-driven strategy of "pharmaceutical health + financial capital" to modernize traditional Chinese medicine [1] - The company has established a robust capital collaborative network, holding 20.11% of Guangfa Securities and being a major shareholder in several pharmaceutical companies, which supports its main business [2][3] Group 2: Financial Performance - In 2023 and 2024, the investment in Guangfa Securities is expected to contribute 1.243 billion and 1.749 billion yuan in revenue, respectively, with a total of 8.757 billion yuan in cash dividends provided to the company [3] - Financial returns are reinvested into the pharmaceutical business, alleviating the high risks and long cycles associated with research and development [3] Group 3: Technological Innovation - The modernization of traditional Chinese medicine relies on modern technology to unlock its core value, transitioning from "experience inheritance" to "scientific decoding" [4] - Jilin Aodong focuses on core material research and is actively involved in cutting-edge fields such as anti-aging and regenerative medicine [4][5] Group 4: Production and Quality Control - The company has developed a closed-loop industrial chain around the breeding, processing, and quality control of its core product, the Aodong deer antler [4][6] - Investments exceeding 46 million yuan have been made to upgrade disease prevention facilities and implement a digital quality control system across its standardized breeding bases [6] Group 5: Future Outlook - Jilin Aodong aims to deepen its dual-driven advantages and integrate new productive forces throughout its industrial development process, focusing on continuous investment in research and intelligent layout [7]
吉林敖东董事长李秀林:“医药健康+金融资本”双轮驱动 走中医药现代化发展之路